These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 26471511)

  • 61. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.
    Namey E; Agot K; Ahmed K; Odhiambo J; Skhosana J; Guest G; Corneli A
    Cult Health Sex; 2016 Sep; 18(9):1081-91. PubMed ID: 27093238
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HIV pre-exposure prophylaxis: Exploring the potential for expanding the role of pharmacists in public health.
    Okoro O; Hillman L
    J Am Pharm Assoc (2003); 2018; 58(4):412-420.e3. PubMed ID: 29789257
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress.
    Mayer KH; Hosek S; Cohen S; Liu A; Pickett J; Warren M; Krakower D; Grant R
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19980. PubMed ID: 26198345
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.
    Elion R; Coleman M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):67-73. PubMed ID: 26599165
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?
    Molina JM; Pintado C; Gatey C; Ponscarme D; Charbonneau P; Loze B; Rozenbaum W; Delaugerre C
    BMC Med; 2013 Aug; 11():186. PubMed ID: 23972284
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HIV prevention trial design in an era of effective pre-exposure prophylaxis.
    Cutrell A; Donnell D; Dunn DT; Glidden DV; Grobler A; Hanscom B; Stancil BS; Meyer RD; Wang R; Cuffe RL
    HIV Clin Trials; 2017; 18(5-6):177-188. PubMed ID: 29039265
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation.
    Marcus JL; Hurley LB; Hare CB; Nguyen DP; Phengrasamy T; Silverberg MJ; Stoltey JE; Volk JE
    J Acquir Immune Defic Syndr; 2016 Dec; 73(5):540-546. PubMed ID: 27851714
    [TBL] [Abstract][Full Text] [Related]  

  • 68. How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2022 Jul; 17(4):213-221. PubMed ID: 35762376
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study.
    MacFadden DR; Tan DH; Mishra S
    J Int AIDS Soc; 2016; 19(1):20791. PubMed ID: 27665722
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.
    Janes H; Corey L; Ramjee G; Carpp LN; Lombard C; Cohen MS; Gilbert PB; Gray GE
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):645-656. PubMed ID: 29732896
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of oral pre-exposure prophylaxis and expanded antiretroviral therapy for preventing HIV infections in the presence of drug resistance among men who have sex with men in China: A mathematical modelling study.
    Jin X; Shi L; Wang C; Qiu T; Yin Y; Shen M; Fu G; Peng Z
    Lancet Reg Health West Pac; 2022 Jun; 23():100462. PubMed ID: 35542892
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis.
    Huang X; Hou J; Song A; Liu X; Yang X; Xu J; Zhang J; Hu Q; Chen H; Chen Y; Meyers K; Wu H
    Front Pharmacol; 2018; 9():799. PubMed ID: 30233355
    [No Abstract]   [Full Text] [Related]  

  • 73. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries.
    Hoornenborg E; Krakower DS; Prins M; Mayer KH
    AIDS; 2017 Oct; 31(16):2179-2191. PubMed ID: 28991023
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Multicomponent Approach to Evaluating a Pre-exposure Prophylaxis (PrEP) Implementation Program in Five Agencies in New York.
    Parisi D; Warren B; Leung SJ; Akkaya-Hocagil T; Qin Q; Hahn I; Stevens L
    J Assoc Nurses AIDS Care; 2018; 29(1):10-19. PubMed ID: 28684224
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Factors Associated With Discussions of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Men Who Have Sex With Men.
    Halton BR; Roberts JNT; Denton GD
    Ochsner J; 2019; 19(3):188-193. PubMed ID: 31528127
    [No Abstract]   [Full Text] [Related]  

  • 76. The Pharmacist's Expanding Role in HIV Pre-Exposure Prophylaxis.
    Farmer EK; Koren DE; Cha A; Grossman K; Cates DW
    AIDS Patient Care STDS; 2019 May; 33(5):207-213. PubMed ID: 31067124
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pre-exposure prophylaxis of HIV.
    Naswa S; Marfatia YS
    Indian J Sex Transm Dis AIDS; 2011 Jan; 32(1):1-8. PubMed ID: 21799568
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?
    Eakle R; Venter F; Rees H
    Retrovirology; 2018 Apr; 15(1):29. PubMed ID: 29609619
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Summary of German-Austrian HIV PrEP guideline.
    Spinner CD; Lang GF; Boesecke C; Jessen H; Schewe K;
    HIV Med; 2019 Jul; 20(6):368-376. PubMed ID: 31140708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.